Celltrion (068270) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Achieved record-high quarterly revenue and profitability in 2Q26, with Young Products driving accelerated growth and Advanced Products maintaining stable performance.
Consolidated H1 2026 revenue was KRW 2,538.7 billion and operating income KRW 773.7 billion, reflecting continued growth from biopharmaceuticals and expanded global sales channels.
Major M&A activities, including the acquisition of GIFRER BARBEZAT and integration of Celltrion Healthcare, strengthened global distribution and manufacturing.
Maintained robust financial position with total assets of KRW 23.7 trillion and equity of KRW 18.0 trillion as of June 2026.
Financial highlights
Total sales reached KRW 1,393.7 billion in 2Q26, up 45.0% YoY and 21.7% QoQ; H1 2026 revenue was KRW 2,538.7 billion.
Operating profit was KRW 451.8 billion in 2Q26, up 86.3% YoY; H1 2026 operating income was KRW 773.7 billion.
Net profit for 2Q26 was KRW 371 billion, up 320.2% YoY; H1 2026 net income was KRW 721.2 billion.
Gross profit margin rose to 62.0% in 2Q26; H1 2026 gross margin was 61.1%.
Young Products sales grew 72.5% YoY to KRW 825 billion; five newly launched products contributed over KRW 300 billion in combined sales.
Outlook and guidance
Annual revenue is projected to outperform initial guidance, supported by rapid market penetration of Young Products.
Management targets FY2026 revenue of KRW 5.3 trillion, with quarterly operating income goals rising from KRW 3,000 billion in Q1 to KRW 6,000 billion in Q4.
Growth momentum anticipated to accelerate in 2H26 through regional expansion, new product launches, and CDMO business focus.
Latest events from Celltrion
- Biosimilar growth and merger integration set an ambitious 2024 outlook, despite profit pressure.068270
Q4 2023 - Portfolio expansion, Zymfentra and AI-enabled R&D anchor the growth roadmap.068270
Investor presentation - Record 2Q24 sales and expanding biosimilar and novel-drug growth plans.068270
Investor presentation - Zymfentra and pipeline growth pair with CDMO expansion and higher shareholder returns.068270
Investor presentation - A broad biosimilar base supports an ADC and multispecific antibody pipeline advancing toward 2028 INDs.068270
Investor presentation - Targets combine rapid product expansion, higher profitability and 40% average shareholder returns.068270
Investor presentation - 2025 targets combine KRW 5T revenue with sharply lower COGS and stronger operating profit.068270
Investor presentation - Young products fuel 1Q growth as FY25 sales are forecast to reach KRW 5tn.068270
Investor presentation - Young-product growth lifted 3Q25 profit as biosimilar launches and capacity expanded.068270
Investor presentation - Young Products drove record Q3 sales and profit, with 4Q growth expected to continue.068270
Q3 2026